Biological Therapy in Previously Treated Patients With Non-small Cell Lung Cancer

Interleukin-2 Plus Activated White Blood Cells in Treating Patients With Cancer That Has Not Responded to Chemotherapy or Radiation Therapy

NCT00019357 ·Status: COMPLETED ·Phase: PHASE1

Interleukin-2 in Treating Patients With Metastatic or Recurrent Kidney Cancer

NCT00002846 ·Status: UNKNOWN ·Phase: PHASE2

Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

NCT00018941 ·Status: COMPLETED ·Phase: PHASE3

Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer

NCT00002504 ·Status: COMPLETED ·Phase: PHASE2

Vaccine Therapy Plus Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer That Has Been Completely Removed in Surgery

NCT00006470 ·Status: COMPLETED ·Phase: PHASE2

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

NCT00019487 ·Status: COMPLETED ·Phase: PHASE2

Interleukin-2 Plus Monoclonal Antibody Therapy in Treating Patients With Solid Tumors

NCT00002994 ·Status: COMPLETED ·Phase: PHASE1

Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung

NCT00005610 ·Status: COMPLETED ·Phase: PHASE2

Biological Therapy in Treating Patients With Metastatic Melanoma

NCT00045149 ·Status: COMPLETED ·Phase: PHASE1

High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma

NCT00003091 ·Status: COMPLETED ·Phase: PHASE2

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer

NCT00006458 ·Status: UNKNOWN ·Phase: PHASE1

Pilot Study of Denileukin Diftitox Plus High-Dose IL-2 for Patients With Metastatic Renal Cancer

NCT00278369 ·Status: COMPLETED ·Phase: EARLY_PHASE1

Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma

NCT00085579 ·Status: WITHDRAWN ·Phase: PHASE2

Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer

NCT00098917 ·Status: TERMINATED ·Phase: PHASE1

High-Dose Intravenous Interleukin-2 in Treating Patients With Metastatic Renal Cell Carcinoma (Kidney Cancer) That Has Not Responded to Previous Low-Dose Intravenous or Subcutaneous Interleukin-2

NCT00080977 ·Status: UNKNOWN ·Phase: PHASE2

Interleukin-2 in Metastatic Melanoma

NCT01702896 ·Status: TERMINATED ·Phase: PHASE2

Biological Therapy in Treating Patients With Metastatic Melanoma

NCT00002786 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma

NCT00005949 ·Status: COMPLETED ·Phase: PHASE2

Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma

NCT00945269 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma

NCT00003568 ·Status: COMPLETED ·Phase: PHASE2

Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma

NCT00303836 ·Status: TERMINATED ·Phase: PHASE2

Trial for the Evaluation of the Effect of Systemic Low-dose Interleukin-2 (IL-2) on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With High Risk Melanoma

NCT00928902 ·Status: COMPLETED ·Phase: PHASE2

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

NCT00019214 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

NCT00006347 ·Status: UNKNOWN ·Phase: PHASE1

Vaccine Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT00019929 ·Status: COMPLETED ·Phase: PHASE2